Precise Bio Overview
Precise Bio is a regenerative medicine company advancing the use of bio-printed tissues and organs in ophthalmology patients. The company is also building a broad portfolio of R&D programs in additional medical disciplines. The company's commercial and R&D programs are based on its 4D bio-fabrication technology. This platform comprises cell expansion, biomaterials, processes, printing technology, and other technologies. The company's technology platform allows it to advance its fabricated human cornea program concurrent with the development of other organs and tissues for use in ophthalmic indications. Moreover, the company's technology overcomes multiple challenges in scalable, reproducible manufacturing of bio-printed tissues and organs. The company maintains offices, laboratories, and production facilities in North Carolina, United States, and Shoham, Israel.
Cumulative Funding Raised Over Time ($)
$15.5MJul 2022
$27.5MJul 2022
$37.5MSep 2017
$37.5MSep 2024
Latest News
growth-positive
בשתי דקות בלבד: בשיבא ידפיסו קרניות להשתלה בבני אדם
The Israeli technology company, פרסייס ביו, has established a 3D printing production line for corneas at the Sheba Medical Center. This marks the first time in the world that a biological production line for 3D-printed corneas has been set up. The company has demonstrated the capability to print functional human biological corneas and successfully implant them in rabbits. They plan to begin human trials in July. This development represents a significant advancement in biotechnology and medical innovation, potentially revolutionizing corneal transplants.
Product Stage
growth-positive
Carl Zeiss Meditec and Precise Bio Announce Partnership in the Development and Commercialization of Tissue-Based Implants for Ophthalmology
Carl Zeiss Meditec has entered into a partnership with Precise Bio to develop and commercialize fabricated corneal tissue for transplants. Carl Zeiss Meditec will invest in Precise Bio and fund the further development of Precise Bios two cornea transplant products. The partnership aims to advance treatment options for corneal disease and elective procedures. Precise Bios 4D bio-fabrication platform allows for the fabrication of tissues by printing cells with structural integrity and long-term cell viability. The companies will jointly develop 4D bio-fabricated corneal transplants for diseases that require endothelial keratoplasty and natural lenticule transplants. The financial terms of the agreement were not disclosed.
PartnersInvestment
growth-positive
איברים מלאכותיים מתאים חיים: עיניים הן רק ההתחלה
Precise Bio, a company specializing in 3D printing of live cells for medical purposes, has raised $13 million in funding. The company was founded by Aryeh Batt, Professor Anthony Atala, and Professor Shay Soker. Precise Bios technology can print artificial corneas and retinas from live cells, with the potential to expand into other organs. The companys products are currently being tested on animals, with human trials expected to start within a year. Precise Bio employs 15 people in Shoham, Israel and the United States.
InvestmentExpand
growth-negative
פרסייס ביו בנבחרת הסטארטאפים 2020 של TheMarker
TheMarkerTechNation reports on the negative impact of the COVID-19 pandemic on the tourism industry and the labor market in Israel. The article highlights a significant decrease in tourist arrivals and a preference among Israelis to vacation abroad. It also mentions signs of weakness in the labor market, with a notable decline in salaries in the high-tech sector and a decrease in the number of employees. TechNation, a company in the high-tech industry, is likely experiencing negative growth as a result of these challenges.
CustomersLayoffs
growth-positive
Precise Bio Developing '4-D' Process for Biofabricating Tissues, Organs
Precise Bio, a regenerative medicine startup, has developed a laser-based biological printer that can fabricate tissues and organs from living cells. The companys vision is to bring regenerative medicine technologies to the clinic to improve quality of life and save lives. Precise Bios initial focus is on ophthalmology applications, particularly corneal transplants. They are also developing a 3-D cardiac tissue patch and evaluating other applications in orthopedics, dentistry, dermatology, and wound care. The global regenerative medicine market is expected to grow to $81 billion by 2023. Precise Bio has raised close to $10 million in private investment and plans to start a Series B round in the third quarter of this year.
CustomersPartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $22M |
| Last funding | Undisclosed |
| Stage | B |
| Rounds | 4 |
| Investors | 4 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | www.precise-bio.com |
Locations
Shaked Street 25, Modi'in-Maccabim-Re'ut, Israel
111 N Chestnut St, Winston-Salem, NC, USA
Photos & Videos
2 item(s)
Precise Bio Business
Business models
B2B
Product stage
R&D
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringTarget Customer
Healthcare & Life SciencesLife SciencesBiotechnologyCore Technology
Materials & SubstancesPlatforms & InterfacesBiologicalsCellsTags (9)
ophthalmologytreatmentsbiotechnology3d-technologyregenerative-medicinelife-sciencesbiomaterialsmedical-technologiestissue-regenerationGeographic Markets
GlobalPrecise Bio Financials
$22M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
B
Funding stage
4
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$15.5MJul 2022
$27.5MJul 2022
$37.5MSep 2017
$37.5MSep 2024
Private Equity Funding
Undisclosed Round
Sep 2024
Undisclosed
Iron Nation
Debt Financing
Jul 2022
$15.53M
K20 Fund, Carl Zeiss
B Round
Jul 2022
$12M
Carl Zeiss (Lead)
,
Aurum Ventures M.K.I, K20 Fund
A Round
Sep 2017
$10M
Aurum Ventures M.K.I
Precise Bio Lifecycle
Cumulative Funding Raised Over Time
$15.5MJul 2022
$27.5MJul 2022
$37.5MSep 2017
$37.5MSep 2024
All Events
Undisclosed Round
Sep 2024
Undisclosed
Iron Nation
Debt Financing
Jul 2022
$15.53M
K20 Fund, Carl Zeiss
B Round
Jul 2022
$12M
Carl Zeiss (Lead)
,
Aurum Ventures M.K.I, K20 Fund
A Round
Sep 2017
$10M
Aurum Ventures M.K.I
Precise Bio News
8 articles
growth-positive
בשתי דקות בלבד: בשיבא ידפיסו קרניות להשתלה בבני אדם
The Israeli technology company, פרסייס ביו, has established a 3D printing production line for corneas at the Sheba Medical Center. This marks the first time in the world that a biological production line for 3D-printed corneas has been set up. The company has demonstrated the capability to print functional human biological corneas and successfully implant them in rabbits. They plan to begin human trials in July. This development represents a significant advancement in biotechnology and medical innovation, potentially revolutionizing corneal transplants.
Product Stage
growth-positive
Carl Zeiss Meditec and Precise Bio Announce Partnership in the Development and Commercialization of Tissue-Based Implants for Ophthalmology
Carl Zeiss Meditec has entered into a partnership with Precise Bio to develop and commercialize fabricated corneal tissue for transplants. Carl Zeiss Meditec will invest in Precise Bio and fund the further development of Precise Bios two cornea transplant products. The partnership aims to advance treatment options for corneal disease and elective procedures. Precise Bios 4D bio-fabrication platform allows for the fabrication of tissues by printing cells with structural integrity and long-term cell viability. The companies will jointly develop 4D bio-fabricated corneal transplants for diseases that require endothelial keratoplasty and natural lenticule transplants. The financial terms of the agreement were not disclosed.
PartnersInvestment
growth-positive
איברים מלאכותיים מתאים חיים: עיניים הן רק ההתחלה
Precise Bio, a company specializing in 3D printing of live cells for medical purposes, has raised $13 million in funding. The company was founded by Aryeh Batt, Professor Anthony Atala, and Professor Shay Soker. Precise Bios technology can print artificial corneas and retinas from live cells, with the potential to expand into other organs. The companys products are currently being tested on animals, with human trials expected to start within a year. Precise Bio employs 15 people in Shoham, Israel and the United States.
InvestmentExpand
growth-negative
פרסייס ביו בנבחרת הסטארטאפים 2020 של TheMarker
TheMarkerTechNation reports on the negative impact of the COVID-19 pandemic on the tourism industry and the labor market in Israel. The article highlights a significant decrease in tourist arrivals and a preference among Israelis to vacation abroad. It also mentions signs of weakness in the labor market, with a notable decline in salaries in the high-tech sector and a decrease in the number of employees. TechNation, a company in the high-tech industry, is likely experiencing negative growth as a result of these challenges.
CustomersLayoffs
growth-positive
Precise Bio Developing '4-D' Process for Biofabricating Tissues, Organs
Precise Bio, a regenerative medicine startup, has developed a laser-based biological printer that can fabricate tissues and organs from living cells. The companys vision is to bring regenerative medicine technologies to the clinic to improve quality of life and save lives. Precise Bios initial focus is on ophthalmology applications, particularly corneal transplants. They are also developing a 3-D cardiac tissue patch and evaluating other applications in orthopedics, dentistry, dermatology, and wound care. The global regenerative medicine market is expected to grow to $81 billion by 2023. Precise Bio has raised close to $10 million in private investment and plans to start a Series B round in the third quarter of this year.
CustomersPartnersInvestment
Cornea Problem? Precise Bio Can Print You Out a New One
growth-positive
Precise Bio opens ophthalmology facility to develop 3D printed corneas
Precise Bio has established a dedicated ophthalmology business unit to advance 3D bioprinting research for the eyes. The company aims to develop autologous cell sourcing, innovative bio-inks, and bioreactors to create functional 3D printed organs. Precise Bios technology has the potential to transform the treatment of serious diseases and address the unmet needs in corneal replacement and other ophthalmic indications. The company is currently pursuing different ophthalmic programs and collaborating with partners. The article highlights advancements in 3D printing in ophthalmology, including the successful 3D printing of human corneas and the development of a 3D corneal biopen. The establishment of the ophthalmology business unit is expected to support Precise Bios future financing strategies and align its financial resources with its technology and intellectual property.
Expand
growth-positive
Precise Bio Announces Launch of Dedicated Ophthalmology Business Unit at AAO 2018
Precise Bio, a regenerative medicine company, has announced the launch of a dedicated ophthalmology business unit to support its expansion into multiple clinical indications. The company has developed a 4D-bio-fabrication technology that allows for the generation of complex tissues in a reproducible manner. Precise Bio is the first company to transplant a 3D-printed cornea graft in animals, demonstrating the feasibility, safety, and efficacy of its technologies. The company aims to advance its printed human cornea program while developing other organs and tissues for ophthalmic indications. The establishment of the ophthalmology business unit aligns with the companys future financing strategies and the estimated $10 billion market value in ophthalmology. The announcement was made at the annual meeting of the American Academy of Ophthalmology.
InvestmentExpand
Precise Bio Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 42 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Precise Bio Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Maor Perlov |
| Registrar ID | 515437358 |
| Crunchbase | precise-bio |
| Phone | +972765391001 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wain@gmail.com |
| Last update | 2022-07-19T00:00:00.000Z |
| Created | 2019-07-16T00:00:00.000Z |